Query: stroke

Filtered By:
Source: American Heart Journal

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 410 results found since Jan 2013.

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: Insights from the TRILOGY ACS Trial
Conclusions Among ACS patients managed without revascularization, use of PPIs did not result in a differential antiplatelet response between prasugrel vs. clopidogrel but was associated with a lower incidence of MI with prasugrel. These hypothesis-generating findings suggest that factors besides platelet reactivity may underlie the differential risk of MI observed by treatment assignment with PPI use.
Source: American Heart Journal - June 11, 2015 Category: Cardiology Source Type: research

Rationale and Design of the Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial
Conclusions The IMPACT trial provides data on different management strategies for risk factor optimization in subjects following cardiovascular procedures. The results will provide a platform for the continued development of novel multidisciplinary interventions in this high-risk population.
Source: American Heart Journal - June 6, 2015 Category: Cardiology Source Type: research

Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in atrial fibrillation patients
Conclusions Urinary 11-dehydro-TxB2 levels are associated with a residual risk of CVEs and CV mortality in AF patients despite anticoagulant treatment.
Source: American Heart Journal - May 23, 2015 Category: Cardiology Source Type: research

Race and Ethnicity Influences on Cardiovascular and Renal Events in Patients with Diabetes Mellitus
Conclusion Despite similar access to care and lower CV event rates, the risk of ESRD was higher among blacks and Hispanics than whites. For blacks, but not Hispanics, this increase was independent of known attributable risk factors.
Source: American Heart Journal - May 23, 2015 Category: Cardiology Source Type: research

Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial
Conclusion In this pilot study of patients with moderate renal insufficiency undergoing cardiac catheterization, with-holding ACEI/ARB resulted in a non-significant reduction in contrast-induced AKI and a significant reduction in post-procedural rise of creatinine. This low cost intervention could be considered when referring a patient for cardiac catheterization.
Source: American Heart Journal - May 12, 2015 Category: Cardiology Source Type: research

Anatomic Runoff Score Predicts Cardiovascular Outcomes in Patients with Lower Extremity Peripheral Artery Disease Undergoing Revascularization
Conclusions After adjustment for clinical factors, the LE-PAD anatomic runoff score was an independent predictor of future cardiovascular morbidity and mortality in a broadly-representative patient population undergoing revascularization for symptomatic PAD. A clinically useful anatomic scoring system, if validated, may assist clinicians in risk-stratification during the course of clinical decision-making.
Source: American Heart Journal - May 2, 2015 Category: Cardiology Source Type: research

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
Conclusions Among patients with AF in US clinical practices, TTR on warfarin is suboptimal, and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Source: American Heart Journal - April 23, 2015 Category: Cardiology Source Type: research

Risk of cardiovascular events and mortality among a population-based cohort of immigrants and long-term residents with diabetes: Are all immigrants healthier and if so, for how long?
Conclusion Immigrants with diabetes are at lower risk of cardiovascular events and mortality compared to long-term residents, an effect that persists more than 10 years after arrival. Not all immigrants demonstrate this health advantage.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Effects of Withdrawing Versus Continuing Renin-Angiotensin Blockers on Incidence of Acute Kidney Injury in Patients with Renal Insufficiency Undergoing Cardiac Catheterization: Results from the CAPTAIN Trial
Conclusion In patients with moderate renal insufficiency undergoing cardiac catheterization, withholding ACEI/ARB reduced (without statistical significance) the incidence of contrast-induced AKI. Additionally, a lower rise in post procedural creatinine levels was also noted. This low cost intervention could be considered when referring a patient for cardiac catheterization.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality
Conclusions Large increases or sustained elevations in hs-CRP over a six-year period were associated with a subsequent increased risk of diabetes; and persons with sustained elevations in hs-CRP were at the highest risk of CVD and mortality. Two measurements of hs-CRP are better than one for characterizing risk and large increases are particularly prognostic.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Novel oral anticoagulants and reversal agents: Considerations for clinical development
This article reflects the views of the authors and should not be construed to represent FDA's views or policies.
Source: American Heart Journal - April 8, 2015 Category: Cardiology Source Type: research

Patients’ Time in Therapeutic Range on Warfarin Among U.S. Atrial Fibrillation Patients: Results from ORBIT-AF Registry
Conclusions Among AF patients in US clinical practices, TTR on warfarin is suboptimal and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research

Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Conclusions We observed consistency of effects in Asian patients receiving ticagrelor and clopidogrel in the PLATO study. The relatively modest number of Asian patients in this analysis supports further investigation of larger cohorts to confirm our observations.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research

Novel Oral Anticoagulants (NOAC) and Reversal Agents: Considerations for Clinical Development
This article reflects the views of the authors and should not be construed to represent FDA’s views or policies.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research

Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography
Conclusions In HCM patients undergoing CPT, a higher % of achieved age-gender predicted VO2 and surgical relief of LVOT obstruction were associated with better outcomes, whereas abnormal HRR, atrial fibrillation, and lower LVEF were associated with worse outcomes.
Source: American Heart Journal - March 10, 2015 Category: Cardiology Source Type: research

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Conclusion ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk.
Source: American Heart Journal - March 10, 2015 Category: Cardiology Source Type: research

Comparison of different interdialytic intervals among hemodialysis patients on their echocardiogram-based cardiovascular parameters
Conclusions In a selective Japanese outpatient population on maintenance HD, there were no differences in resting cardiovascular function measured by echocardiography at 3 different IDTs. However, exercise-induced afterload mismatch assessed by the changes in Ea, SV, SW, and SW/PVA efficiency was most pronounced in individuals after the long IDT compared with other IDTs. Our findings report potential pathophysiologic echocardiographic parameters that attempt to explain why cardiovascular events are highest on the day after the long IDT compared to other IDTs in dialysis patients.
Source: American Heart Journal - March 10, 2015 Category: Cardiology Source Type: research

A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF STUDY)
Publication date: Available online 21 February 2015 Source:American Heart Journal Author(s): Gregory Y.H. Lip , Jose Merino , Michael Ezekowitz , Kenneth Ellenbogen , Dmitry Zamoryakhin , Hans Lanz , James Jin , Naab Al-Saadi , Michele Mercuri , Andreas Goette We designed a prospective, randomized, open-label, blinded endpoint evaluation(PROBE) parallel group Phase 3b clinical trial comparing edoxaban (a new oral factor Xa inhibitor) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of non-valvular AF. The primary efficacy endpoint is the composite endpoints of st...
Source: American Heart Journal - February 25, 2015 Category: Cardiology Source Type: research

Predictors of long-term outcomes in hypertrophic cardiomyopathy patients undergoing cardiopulmonary stress testing and echocardiography
Conclusions In HCM patients undergoing CPT, a higher % of achieved age-gender predicted V02 and surgical relief of LVOT obstruction were associated with better outcomes, while abnormal HRR, atrial fibrillation and lower LVEF were associated with worse outcomes.
Source: American Heart Journal - February 25, 2015 Category: Cardiology Source Type: research

Rationale, design, and baseline characteristics in Elixa, a long-term cardiovascular endpoint trial of Lixisenatide versus Placebo
Conclusion ELIXA will be the first trial to report the safety and efficacy of a GLP-1RA in people with T2DM and high CV-event risk.
Source: American Heart Journal - February 13, 2015 Category: Cardiology Source Type: research

Comparison of Different Inter-dialytic Intervals Among Hemodialysis Patients on Their Echocardiogram-Based Cardiovascular Parameters
Conclusions In a selective Japanese outpatient population on maintenance hemodialysis, there were no differences in resting cardiovascular function measured by echocardiography at three different IDTs. However, exercise-induced afterload mismatch assessed by the changes in Ea, SV, SW and SW/PVA efficiency was most pronounced in individuals following the long IDT compared with other IDTs. Our findings report potential pathophysiologic echocardiographic parameters that attempt to explain why cardiovascular events are highest on the day after the long IDT compared to other IDTs in dialysis patients.
Source: American Heart Journal - February 13, 2015 Category: Cardiology Source Type: research

Impact of Obstructive Sleep Apnea and Continuous Positive Airway Pressure Therapy on Outcomes in Patients with Atrial Fibrillation – Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Conclusion Compared with those without, AF patients with obstructive sleep apnea have worse symptoms and higher risks of hospitalization, but similar mortality, major adverse cardiovascular outcome and AF progression rates. Clinical Trial Registration: NCT01165710 (http://www.clinicaltrials.gov)
Source: American Heart Journal - February 7, 2015 Category: Cardiology Source Type: research

Anticoagulant Therapy and Outcomes in Patients With Prior or Acute Heart Failure and Acute Coronary Syndromes: Insights From the APixaban for PRevention of Acute ISchemic Events 2 (APPRAISE-2) Trial
Conclusions In high-risk patients post-ACS, both prior and acute HF are associated with an increased risk of subsequent clinical events. Apixaban did not significantly reduce clinical events and increased bleeding in patients with and without HF; however, there was a tendency toward fewer clinical events with apixaban in patients with acute HF.
Source: American Heart Journal - January 13, 2015 Category: Cardiology Source Type: research

Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in non-valvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF)
In conclusion, X-TRA and CLOT-AF will provide some answers to the many unresolved issues concerning patient outcomes and prognostic factors in patients with AF and LAA thrombi. Results from this study program would provide the first prospective interventional study (X-TRA) and a large international retrospective observational registry (CLOT-AF) on the prevalence and natural history of LA/LAA thrombi. Unique data on clot resolution with rivaroxaban in a prospective cohort would be obtained in X-TRA.
Source: American Heart Journal - January 6, 2015 Category: Cardiology Source Type: research

Rational and Design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China
Conclusions The CPACS-3 study will be the first large randomized trial with sufficient power to assess the effects of a multi-faceted quality of care improvement initiative on hard clinical outcomes, in patients with ACS.
Source: American Heart Journal - December 19, 2014 Category: Cardiology Source Type: research

Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding
Publication date: January 2015 Source:American Heart Journal, Volume 169, Issue 1 Author(s): John A. Cairns , Jeffrey I. Weitz
Source: American Heart Journal - December 9, 2014 Category: Cardiology Source Type: research

Off-hour admission and outcomes for patients with acute myocardial infarction undergoing percutaneous coronary interventions
Conclusions Patients who were admitted during off-hours did not have higher mortality or readmission rates as compared with ones admitted during regular hours at an academic medical center.
Source: American Heart Journal - December 9, 2014 Category: Cardiology Source Type: research

Cardiovascular prognosis in patients with type 2 diabetes: Contribution of heart and kidney subclinical damage
Conclusions Electrocardiographic LVH is complementary to kidney damage for MACE prediction in T2D.
Source: American Heart Journal - December 9, 2014 Category: Cardiology Source Type: research

Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents
Conclusions Small absolute differences in the risk of ischemic events with longer DAPT would be sufficient to outweigh the known bleeding risks.
Source: American Heart Journal - December 2, 2014 Category: Cardiology Source Type: research

Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Marco Valgimigli Background Transradial intervention (TRI) and bivalirudin infusion compared with transfemoral coronary intervention or unfractionated heparin plus glycoprotein IIb/IIIa inhibitors decrease bleeding complications in patients with acute coronary syndromes (ACS). Although bleeding is thought to be associated with worse outcomes, it remains unclear whether TRI and bivalirudin both independently lower ischemic or combined ischemic and bleeding complications in ACS patients undergoing contemporary invasive management....
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research

Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Conclusions We observed no interaction between vorapaxar and clopidogrel after non–ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism.
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research

Antistreptokinase antibodies and outcome of fibrinolytic therapy with streptokinase for left-sided prosthetic valve thrombosis
Conclusion Anti-SK antibody titers are not associated with success of fibrinolytic therapy using SK in patients with left-sided PVT.
Source: American Heart Journal - November 17, 2014 Category: Cardiology Source Type: research

Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare duration of dual antiplatelet therapy after drug-eluting stents
Conclusions Small absolute differences in the risk of ischemic events with longer DAPT would be sufficient to outweigh the known bleeding risks.
Source: American Heart Journal - November 17, 2014 Category: Cardiology Source Type: research

Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: Design of the randomized antarctic study
Conclusion ANTARCTIC is a nationwide, prospective, open-label study testing a strategy of platelet function monitoring with dose and drug adjustment to reduce ischemic and bleeding complications in elderly ACS patients undergoing coronary stenting.
Source: American Heart Journal - October 31, 2014 Category: Cardiology Source Type: research

Anti-streptokinase antibodies and outcome of fibrinolytic therapy with streptokinase for left-sided prosthetic valve thrombosis
Conclusion Anti-SK antibody titres are not associated with success of fibrinolytic therapy using SK in patients with left-sided PVT.
Source: American Heart Journal - October 31, 2014 Category: Cardiology Source Type: research

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Publication date: Available online 7 August 2014 Source:American Heart Journal Author(s): Gregory G. Schwartz , Laurence Bessac , Lisa G. Berdan , Deepak L. Bhatt , Vera Bittner , Rafael Diaz , Shaun G. Goodman , Corinne Hanotin , Robert A. Harrington , J. Wouter Jukema , Kenneth W. Mahaffey , Angèle Moryusef , Robert Pordy , Matthew T. Roe , Tyrus Rorick , William J. Sasiela , Cheerag Shirodaria , Michael Szarek , Jean-François Tamby , Pierluigi Tricoci , Harvey White , Andreas Zeiher , Philippe Gabriel Steg Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to le...
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
Conclusions This trial is evaluating LDL-C lowering beyond previously targeted LDL-C levels. The results depend on achieving the desired separation of LDL-C with ezetimibe and on the assumption that ezetimibe’s lowering of LDL-C will have similar event reduction efficacy as the LDL-C lowering from a statin. The results could affect future therapies and guidelines.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy
Conclusions In stable post-MI patients on evidence-based medical therapy, the combination of oral high-dose vitamins and chelation therapy compared with double placebo reduced clinically important cardiovascular events to an extent that was both statistically significant and of potential clinical relevance.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
Conclusions LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
Conclusions Comprehensive procedures were used for rigorous event reascertainment and readjudication in a previously completed open-label, global clinical trial. These procedures used in this unique situation were consistent with other common approaches in the field, were enhanced to address the FDA concerns about the original RECORD trial results, and could be considered by clinical trialists designing event readjudication protocols for drug development programs that have been completed.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
Conclusions Among older patients with AF and CAD, overall warfarin use was low. Patients ≥80 years old at highest stroke risk received warfarin in similar proportions to the overall cohort. Further investigation into optimizing antithrombotic strategies in this population is warranted.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

A multifaceted intervention to narrow the evidence-based gap in the treatment of acute coronary syndromes: Rationale and design of the Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes (BRIDGE-ACS) cluster-randomized trial
Publication date: March 2012 Source:American Heart Journal, Volume 163, Issue 3 Author(s): Otávio Berwanger , Hélio P. Guimarães , Ligia N. Laranjeira , Alexandre B. Cavalcanti , Alessandra Kodama , Ana Denise Zazula , Eliana Santucci , Elivane Victor , Uri A. Flato , Marcos Tenuta , Vitor Carvalho , Vera Lucia Mira , Karen S. Pieper , Luiz Henrique Mota , Eric D. Peterson , Renato D. Lopes Translating evidence into clinical practice in the management of acute coronary syndromes (ACS) is challenging. Few ACS quality improvement interventions have been rigorously evaluated to determine their impact on patient care and ...
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research

Transcatheter aortic valve replacement: Historical perspectives, current evidence, and future directions
Severe aortic stenosis (AS) results in considerable morbidity and mortality without aortic valve replacement and is expected to increase in prevalence with the aging population. Because AS primarily affects the elderly, many patients with comorbidities are poor candidates for surgical aortic valve replacement (SAVR) and may not be referred. Transcatheter aortic valve replacement (TAVR) has emerged as transformative technology for the management of AS over the past decade. Randomized trials have established the safety and efficacy of TAVR with improved mortality and quality of life compared with medical therapy in inoperabl...
Source: American Heart Journal - July 30, 2014 Category: Cardiology Authors: Aaron Horne, Elizabeth A. Reineck, Rani K. Hasan, Jon R. Resar, Matthews Chacko Tags: Curriculum in Cardiology Source Type: research

Clinical outcomes of hybrid coronary revascularization versus coronary artery bypass surgery in patients with diabetes mellitus
Background: Hybrid coronary revascularization (HCR) involves minimally invasive left internal mammary artery to left anterior descending coronary artery grafting combined with percutaneous coronary intervention (PCI) of non–left anterior descending vessels. The safety and efficacy of HCR among diabetic patients are unknown.Methods: Patients with diabetes were included who underwent HCR at a US academic center between October 2003 and September 2013. These patients were matched 1:5 to similar patients treated with coronary artery bypass grafting (CABG) using a propensity score (PS)-matching algorithm. Conditional logistic...
Source: American Heart Journal - July 14, 2014 Category: Cardiology Authors: Ralf E. Harskamp, Patrick F. Walker, John H. Alexander, Ying Xian, Henry A. Liberman, Robbert J. de Winter, Thomas A. Vassiliades, Eric D. Peterson, John D. Puskas, Michael E. Halkos Tags: Diabetes and Metabolism Source Type: research

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
Background: In the TRACER trial, vorapaxar, a protease-activated receptor-1 antagonist, plus standard care in non–ST-segment elevation acute coronary syndrome (NSTE ACS) patients did not significantly reduce the primary composite end point but reduced a key secondary end point and significantly increased bleeding. History of peripheral artery disease (PAD) was a risk-enrichment inclusion criterion. We investigated the efficacy and safety of vorapaxar in NSTE ACS patients with documented PAD.Methods: TRACER was a double-blind, randomized trial comparing vorapaxar with placebo in 12,944 patients with NSTE ACS.Results: In t...
Source: American Heart Journal - July 7, 2014 Category: Cardiology Authors: William Schuyler Jones, Pierluigi Tricoci, Zhen Huang, David J. Moliterno, Robert A. Harrington, Peter R. Sinnaeve, John Strony, Frans Van de Werf, Harvey D. White, Claes Held, Paul W. Armstrong, Philip E. Aylward, Edmond Chen, Manesh R. Patel, Kenneth W. Tags: Peripheral Vascular Disease Source Type: research

Finding atrial fibrillation in stroke patients: Randomised evaluation of enhanced and prolonged Holter-monitoring - Find-AF -Rationale and Design
Source: American Heart Journal - July 3, 2014 Category: Cardiology Authors: Mark Weber-Krüger, Götz Gelbrich, Raoul Stahrenberg, Jan Liman, Pawel Kermer, Gerhard F. Hamann, Joachim Seegers, Klaus Gröschel, Rolf Wachter, Find-AFRANDOMISED investigators Source Type: research

Dual antiplatelet therapy in patients with stable coronary artery disease in modern practice: Prevalence, correlates, and impact on prognosis (from the Suivi d’une cohorte de patients COROnariens stables en region NORd-Pas-de-Calais study)
Conclusions: Our study shows that a significant proportion of stable CAD patients are treated with DAPT in modern practice. Several correlates of DAPT were identified. Although no increase in bleeding was observed, our results do not support the prescription of prolonged DAPT.
Source: American Heart Journal - June 23, 2014 Category: Cardiology Authors: Gilles Lemesle, Nicolas Lamblin, Thibaud Meurice, Olivier Tricot, Robert Lallemant, Olivier Nugue, Maxence Delomez, Octave Equine, Sylvie Tondeux, Christophe Bauters Tags: Coronary Artery Disease Source Type: research

National Trends in Stroke after Acute Myocardial Infarction among Medicare Patients in the United States: 1999-2010
Source: American Heart Journal - June 14, 2014 Category: Cardiology Authors: Yun Wang, Judith H. Lichtman, Kumar Dharmarajan, Frederick A. Masoudi, Joseph S. Ross, John A. Dodson, Jersey Chen, John A. Spertus, Sarwat I. Chaudhry, Brahmajee K. Nallamothu, Harlan M. Krumholz Source Type: research

Parathyroid hormone concentration and risk of cardiovascular diseases: The Atherosclerosis Risk in Communities (ARIC) study
Conclusions: This large prospective study failed to support the hypothesis that elevated PTH is an independent risk marker for incident CVD. When our data were added to the previous meta-analysis, the pooled hazard ratio remained statistically significant but weakened.
Source: American Heart Journal - June 11, 2014 Category: Cardiology Authors: Aaron R. Folsom, Alvaro Alonso, Jeffrey R. Misialek, Erin D. Michos, Elizabeth Selvin, John H. Eckfeldt, Josef Coresh, James S. Pankow, Pamela L. Lutsey Tags: Coronary Artery Disease Source Type: research